Your browser doesn't support javascript.
loading
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Ashina, Messoud; Mitsikostas, Dimos D; Amin, Faisal Mohammad; Kokturk, Pinar; Schankin, Christoph J; Sahin, Gurdal; Pozo-Rosich, Patricia; Dorman, Paul J; Nezádal, Tomás; Poole, Anne Christine; Martins, Isabel Pavão; Sumelahti, Marja-Liisa; Ramirez Campos, Verena; Ahn, Andrew H; Lyras, Leonidas; Tassorelli, Cristina.
Afiliación
  • Ashina M; Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Mitsikostas DD; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Amin FM; First Department of Neurology, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Kokturk P; Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Schankin CJ; Department of Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Sahin G; Teva Netherlands B.V., Amsterdam, Netherlands.
  • Pozo-Rosich P; Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Dorman PJ; Department of Clinical Sciences of Lund, Lund University, Skåneuro Neurology Clinic, Lund, Sweden.
  • Nezádal T; Headache Unit & Research Group, Vall d'Hebron Hospital & Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Poole AC; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Martins IP; Institute of Neuropsychiatric Care, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Sumelahti ML; Private Practice: Oslo Headache Centre, Oslo, Norway.
  • Ramirez Campos V; Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Ahn AH; Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
  • Lyras L; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
  • Tassorelli C; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Cephalalgia ; 43(11): 3331024231214987, 2023 11.
Article en En | MEDLINE | ID: mdl-37987641
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trastornos Migrañosos / Anticuerpos Monoclonales Límite: Adult / Humans Idioma: En Revista: Cephalalgia Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trastornos Migrañosos / Anticuerpos Monoclonales Límite: Adult / Humans Idioma: En Revista: Cephalalgia Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca